Tag: spurned
Intercept’s NASH hopeful spurned by FDA, raising questions for other companies...
Intercept Therapeutics, long the frontrunner in non-alcoholic steatohepatitis (NASH), has suffered several delays on its FDA application for obeticholic acid (OCA). Now, the company has received an...